IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS

被引：0
|
作者：
Kovtun, Y. [1 ]
Jones, G. [1 ]
Harvey, L. [1 ]
Rui, L. [1 ]
Audette, C. [1 ]
Liu, F. [1 ]
Bai, C. [1 ]
Wilhelm, A. [1 ]
Yoder, N. C. [1 ]
Adams, S. [1 ]
Goldmacher, V. S. [1 ]
Chari, R. [1 ]
Chittenden, T. [1 ]
机构：
[1] ImmunoGen Inc, Waltham, MA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB582
引用
收藏
页码：222 / 222
页数：1
相关论文
共 50 条
  • [41] DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
    Okajima, Daisuke
    Yamaguchi, Junko
    Kitamura, Michiko
    Kamei, Reiko
    Maejima, Takanori
    Shibutani, Tomoko
    Yasuda, Satoru
    Toki, Tadashi
    Karibe, Tsuyoshi
    Fujitani, Tomomichi
    Nakada, Takashi
    Goto, Riki
    Noguchi, Yutaka
    Abe, Yuki
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [42] Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies
    Abrahams, Cristina
    Li, Xiaofan
    DeAlmeida, Venita
    Embry, Millicent
    Yu, Abigail
    Krim, Stellanie
    Hoffmann, Heidi
    Zawada, James
    Bruhns, Maureen
    Matheny, Shannon
    Bussell, Stuart
    Kline, Toni
    Yam, Alice
    Stafford, Ryan
    Hallam, Trevor
    Lupher, Mark
    Molina, Arturo
    CANCER RESEARCH, 2017, 77
  • [43] A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL
    Gehlert, C. L.
    Schewe, D. M.
    Klausz, K.
    Schrappe, M.
    Cario, G.
    Baldus, C. D.
    Gramatzki, M.
    Lenk, L.
    Kellner, C.
    Peipp, M.
    KLINISCHE PADIATRIE, 2024, 236 (03): : 205 - 205
  • [44] The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
    Beckwith, K. A.
    Frissora, F. W.
    Stefanovski, M. R.
    Towns, W. H.
    Cheney, C.
    Mo, X.
    Deckert, J.
    Croce, C. M.
    Flynn, J. M.
    Andritsos, L. A.
    Jones, J. A.
    Maddocks, K. J.
    Lozanski, G.
    Byrd, J. C.
    Muthusamy, N.
    LEUKEMIA, 2014, 28 (07) : 1501 - 1510
  • [45] Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Zhu, Liang
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
  • [46] HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
    Xu, Yan
    Liang, Junqing
    Jiang, Shuwen
    Yang, Haibin
    Zhang, Hui
    Mao, Fangfang
    Zhu, Jiahuan
    He, Jianlin
    Yang, Na
    Wang, Jian
    Zhang, WeiHan
    Ren, Yongxin
    Su, Weiguo
    CANCER RESEARCH, 2024, 84 (06)
  • [47] A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics
    Zhong, Haihong
    Xiong, Yan
    Huang, Han
    Pan, Yuming
    Wang, Na
    Sun, Bin
    Liu, Shen
    Yuan, Wei
    Liu, Dingguo
    Fang, Jan
    Bao, Haifeng
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL)
    Arribas, Alberto J.
    Cascione, Luciano
    Aresu, Luca
    Gaudio, Eugenio
    Rinaldi, Andrea
    Tarantelli, Chiara
    Akhmedov, Murodzhon
    Zucca, Emanuele
    Rossi, Davide
    Stathis, Anastasios
    Bertoni, Francesco
    CANCER RESEARCH, 2018, 78 (13)
  • [49] DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
    Yamato, Michiko
    Hasegawa, Jun
    Maejima, Takanori
    Hattori, Chiharu
    Kumagai, Kazuyoshi
    Watanabe, Akiko
    Nishiya, Yumi
    Shibutani, Tomoko
    Aida, Tetsuo
    Hayakawa, Ichiro
    Nakada, Takashi
    Abe, Yuki
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 635 - 646
  • [50] DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models
    Yamato, M.
    Hasegawa, J.
    Hattori, C.
    Maejima, T.
    Shibutani, T.
    Deguchi, T.
    Izumi, N.
    Watanabe, A.
    Nishiya, Y.
    Nakada, T.
    Abe, Y.
    Agatsuma, T.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S14 - S15
12345